carbamazepine TEGRETOL

Class: AED/​Mood Stabilizer
FDA Indications: Epilepsy, Trigeminal Neuralgia, Bipolar Disorder
Off-Label Use: Restless Leg Syndrome, Neuropathic Pain, Agitation And Aggression In Dementia
Forms: 100, 200mg tablet; 100, 200, 400 mg Extended-Release Capsules (Equetro®); 100 mg/5 mL po soln
Dose Range: 200-1600 mg/day
Starting: Usual starting dose is 200 mg BID, gradually increasing up to an average effective dose of 400 mg BID. The maximum recommended dose is 1600 mg QD (split BID).
Monitoring: Every 6 to 12 months: CBZ levels (therapeutic range 4-12 μg/mL), LFTs, CBC w/ diff & retics, serum Na+

NAMI drug fact sheet

Contraindications: H/o bone marrow depression, known sensitivity to any of the TCAs, concomitant use of MAOIs
Serious Side Effects: Stevens-Johnson syndrome/TEN (1-6:10,000, 10x higher in some Asian countries), aplastic anemia (2:1,000,000), agranulocytosis (6:1,000,000), ↑'d suicidality, DRESS
Side Effects: sedation/somnolence (32%), dizziness (44%), ataxia, hyperhidrosis, rash, pruritus, speech disturbance, xerostomia, constipation, anemia, visual changes, weakness/asthenia, hyponatremia, leukopenia, nausea (29%), vomiting (18%)
1° MOA: Binds to α subunit of voltage sensitive Na+ channels & possibly actions at other ion channels (Ca2+ & K+). Interference with these channels may enhance the inhibitory actions of GABA.
Target: SCN5A
t½: 35 (28-65)° TMAX: 4-8°
Substrate of: 3A4; 2C8, 1A2
Inhibits: ∅ ; Induces: 1A2, 2A6, 2B6, 2C9, 2C19, 3A4, UGTs & mEH
Active Metabolites: carbamazepine-10,11-epoxide
  • - pan-inducer of nearly all major metabolic pathways
  • - induces its own metabolism — autoinduction may start within 24° of 1st dose & seems to be complete within 20-30 days
  • - autoinduction of CBZ is dose dependent, so each dose ↑ will result in further autoinduction
  • - combining with Li+ can ↑ neurotoxic side effects
  • - DO NOT CO-PRESCRIBE WITH MAOIs (need a 14-day washout period)
  • - t½ after a single dose varies between 28-65°, however after autoinduction is completed t½'s are in the range of 10-20°
  • - HLA Genetic Testing recommened patients of East Asian descent who are at an ↑'d risk of carbamazepine-induced SJS
  • - ∅ clinically significant weight gain
  • - has most robust evidence, among mood-stabilizers, for use in treating non-cognitive symptoms of dementia
Special Populations

Category D—CBZ can cause fetal harm (spina bifida) when administered to a pregnant woman. Fetal plasma concentrations range between 50-80% of maternal levels. CBZ is cleared more rapidly in the 3rd trimester

RID 1.1-7.3%; some AEs reported, suggest discontinue or bottle feed

Clearance is age dependent, with higher clearance reported in younger children and lower clearances reported in older patients

Renal disease and dialysis do not alter clearance

Patients with significant liver disease may have a decreased clearance of carbamazepine


Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 29 2024 20:54:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.